Cubist unveils five-year strategic goals; enters antibiotics collaboration

USA-based Cubist Pharmaceuticals (Nasdaq: CBST) has announced its five-year strategic aspirations – Building Blocks of Growth – at its Investor Day at the Nasdaq Market Site. Cubist’s president and chief executive Michael Bonney outlined goals for top- and bottom-line growth, future pipeline developments, and cultural elements that will position Cubist to deliver long-term, sustainable growth.

Cubist expects to:

• grow global revenue to $2 billion annually;
• have four product candidates in late-stage clinical trials;
• generate $700 million in non-GAAP annual adjusted operating income; and
• continue to strengthen and develop the company’s highly differentiated culture.